PRINCETON, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will present new pre-clinical data highlighting its ...
Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at ...
Daniel C. Cattran, MD The MENTOR study is poised to change first-line-treatment recommendations for idiopathic membranous nephropathy. The Membranous Nephropathy Trial of Rituximab (MENTOR) study is ...
Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...
Preclinical data for CLYM116, anti-APRIL monoclonal antibody, highlight favorable pharmacokinetic and pharmacodynamic profile, supporting development for IgA nephropathy (IgAN) Long-term follow-up ...
In a study, approximately one-third of patients with lupus membranous nephritis tested positive for the proteins exostosin 1/exostosin 2. Among patients with lupus membranous nephritis (LMN), those ...
Treatment with methylprednisolone plus a cytotoxic drug improves remission rates and 10-year survival in patients with membranous nephropathy, but can have adverse effects. In patients with membranous ...
- 48-week data show a 64% decrease from baseline in proteinuria in IgA nephropathy, 82% decrease from baseline in proteinuria in primary membranous nephropathy, and stabilization of estimated ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced updated data for povetacicept (pove) in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) from the ongoing RUBY-3 trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results